Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

---- 25,662,961 34,701,071 ------------------------------------------------------------------------- Property and equipment 222,312 208,320 Long term investment 684,000 684,000 ------------------------------------------------------------------------- 26,569,273 35,593,391 ------------------------------------------------------------------------- ------------------------------------------------------------------------- LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities 3,639,572 4,226,933 ------------------------------------------------------------------------- Shareholders' equity Share capital Authorized: unlimited number of common shares Issued: 61,569,969 (December 31, 2009 - 61,549,969) 131,980,274 131,908,274 Warrants 2,073,441 4,511,441 Contributed surplus 16,157,171 13,734,743 Deficit (127,281,185) (118,788,000) ------------------------------------------------------------------------- 22,929,701 31,366,458 ------------------------------------------------------------------------- 26,569,273 35,593,391 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Oncolytics Biotech Inc. CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (unaudited) Three Month Three Month Six Month
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 ... Company specializing in cannabis formulation-based drug development and ... New York Times for taking a strong position ... in its Sunday, July 27, 2014 publication.  The ... upcoming editorials and articles this week exploring the ...
(Date:7/29/2014)... HILLS, Calif. , July 29, 2014 /PRNewswire/ ... specializing in personalized medicine, treatment of infectious diseases ... strategies of prognosis and prevention of pathologies like ... of August 1, 2014, ImmunoClin Corporation will complete ... Washington, D.C. , a key ...
(Date:7/29/2014)... 29, 2014 TransVac Solutions, the trusted ... and transport solutions for hospitals, will be exhibiting at ... (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 in ... technology for making hospitals cleaner, reducing infection risk and ... hospital’s life cycle. Staff will be available at ...
(Date:7/29/2014)... July 29, 2014 July 29, ... pioneer in the biotechnology industry, announced that it ... Securities, Inc. to explore financing opportunities that build ... a breakthrough vaccine platform with the potential to ... company exclusively licensed the well-established LAMP platform from ...
Breaking Biology Technology:Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... Inc.,(Nasdaq: ENMD ) a clinical-stage pharmaceutical company ... diseases,announced today that James S. Burns, President and ... the ThinkEquity Partners, 5th Annual,Growth Conference, to be ... Francisco,California, September 17-20, 2007. Mr. Burns, presentation is ...
... Sept. 13 VaxGen,Inc. (Pink Sheets: VXGN) today ... to align its cost structure with,its pursuit of ... VaxGen is reducing its workforce from 61 to ... monthly cash expenditures used in operating,activities to $1.4 ...
... COLUMBIA, Md., Sept. 13 Martek Biosciences,Corporation (Nasdaq: ... presenting at the,upcoming UBS Global Life Sciences Conference ... September 24-27, 2007 at the Grand Hyatt in ... on Tuesday, September 25th at,3:00 p.m. Eastern Time. ...
Cached Biology Technology:EntreMed to Present at ThinkEquity Partners' 5th Annual Growth Conference 2VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives 2
(Date:7/29/2014)... YORK , July 29, 2014  When it comes to ... new devices, if not the last. However, when it comes to ... Though the market for the Internet of Things and its ... make an impact in the healthcare industry, whether it,s in the ... to keep us fit. With that in mind, InformationWeek ...
(Date:7/29/2014)... an easier method to create DNAprotein conjugates. The ... diagnosing diseases. , DNA linked to proteins ... can be used in diagnostic techniques, nanotechnology and ... with DNA can be used for purposes ... biological material. The method also provides easier access ...
(Date:7/29/2014)... (UM SOD) and Medicine (UM SOM) jointly announced ... million grant award from the National Institute of ... Institutes of Health to study the causes, prevention ... which renews a previous $12 million five-year NIAID-funded ... research by studying chlamydial and gonorrheal diseases as ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
... work in protein production, a Princeton-led team has discovered ... doing so, they also have discovered how one protein ... cancer-fighting process. In a study appearing in the ... Thomas Silhavy, Princeton,s Warner-Lambert Parke-Davis Professor of Molecular Biology, ...
... Virginia Tech has shown that the oldest complex life ... million years ago likely fed by osmosis. ... the fern-shaped rangeomorphs and the air mattress-shaped erniettomorphs. These ... through their outer membrane, much like modern microscopic bacteria, ...
... under the summer heat, consider this: your child may ... cool old days." To illustrate expected increases in extreme ... projections made with global climate models. Scientific literature ... hot days, "heat waves" (very high temperatures sustained over several ...
Cached Biology News:Princeton team learns why some drugs pack such a punch 2Princeton team learns why some drugs pack such a punch 3Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 2Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 3Those dog days of August: 3 times the heat by 2050? 2
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... rapid and efficient removal of short primers, ... from PCR products (Figure 1). The simple ... Buffer options for fragments >100 bp or ... either single column or 96-well plate format ...
... capped transcripts with the translation boosting Cap ... 100% capped (versus 40% to 80% capped ... about 2 hours. mScript™ also features the ... to be up to 50% more efficient ...
... Baculovirus Expression System with Gateway™ Technology ... plasmids containing the polyhedrin promoter. The ... baculovirus genome (bacmid DNA) by site-specific ... cells. The recombinant bacmid DNA is ...
Biology Products: